Endocrinology

13,14-Dihydro-15-keto-PGE1 is an inactive metabolite of PGE1. 13, 14-Dihydro-15-Keto-pGE1 inhibited platelet aggregation in ADP-induced human isolated platelet-rich plasma with IC₅₀ 14.8 μg/mL.

RET-IN-32 is an orally active RET inhibitor with IC₅₀ values of 0.285, 4.602 and 103.5 nM against wild-type, V804M and G810S mutant forms, respectively. RET-IN-32 inhibits the autophosphorylation of Tyr1062. RET-IN-32 completely suppresses tumor growth induced by BAF3-KIF3B-RET-WT xenografts. RET-IN-32 can be used in the research of thyroid cancer and lung cancer.

20-Hydroxy Prostaglandin E2 (20-Hydroxy-PGE2) is a metabolite of Prostaglandin E2 (HY-101952) that can be metabolized by cytochrome P450.

DS-1501 is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

CX08005 is a competitive PTP1B inhibitor. CX08005 can directly enhance the action of insulin in vivo and in vitro and improve insulin resistance.

C20 Sphingomyelin (d18:1/20:0) (N-eicosanoyl-D-erythro-Sphingosylphosphorylcholine; SM(d18:1/20:0)) is a naturally occurring sphingolipid. C20 Sphingomyelin (d18:1/20:0) levels are upregulated in the hippocampus of streptozotocin (HY-13753)-induced diabetic rats and in human plasma, positively correlating with insulin resistance in obese humans. C20 Sphingomyelin (d18:1/20:0) is also upregulated in the liver of a mouse model of Niemann-Pick C1 disease, a neurodegenerative cholesterol sphingolipid lysosomal storage disorder.

ONO 1082 is a Prostaglandin E1 (PGE1) (HY-B0131) derivative and increases cAMP level in hepatocytes. ONO 1082 competes with the action of the cholestatic factor through the increase in the cAMP level.

Cimbuterol (Standard) is the analytical standard of Cimbuterol (HY-131105). This product is intended for research and analytical applications. Cimbuterol is a β-adrenergic agonist. β-adrenergic agonists act as bronchodilators and tocolytics. β-adrenergic agonists promote growth.

Deflazacort-d₅ is the deuterium labeled Deflazacort. Deflazacort, a glucocorticoid, is an inactive proagent and is converted rapidly to the active metabolite 21-desacetyldeflazacort. Deflazacort is used as an anti-inflammatory and immunosuppressant.

Hydrocortisone-OVA is a conjugate of Hydrocortisone (HY-N0583) and OVA peptide. Hydrocortisone (Cortisol) is a steroid hormone or glucocorticoid secreted by the adrenal cortex.

PU 2049 is a Melatonin (HY-B0075) derivative. PU 2049 exhibits greater efficacy than Melatonin in reducing skin scaling and erythematous papular lesions. PU 2049 can be used in the research of psoriasis.

GPR54 antagonist‑1 is a GPR54 antagonist with IC₅₀ values of 3.6 nM and 15 nM against human and rat GPR54, respectively. GPR54 antagonist‑1 shows blood‑brain barrier penetration. GPR54 antagonist‑1 blocks the function of human and rat GPR54 receptors. GPR54 antagonist‑1 suppresses plasma luteinizing hormone levels in castrated male rats. GPR54 antagonist‑1 can be used for the study of prostate cancer and endometriosis.

α-Glucosidase-IN-4 is a reversible and mixed type α-glucosidase inhibitor with an IC₅₀ of 12.98 μM, a K_I of 27.02 μM, and a K_IS of 13.65 μM, respectively.

ADRA1D receptor antagonist 1 (free base) (compound (R)-9s) is an orally active, potent and selective human α_1D-adrenoceptor (α_1D-AR) antagonist (K_i=1.6 nM). ADRA1D receptor antagonist 1 (free base) dose-dependently inhibits bladder contraction with an IC₃₀ value of 15 nM. ADRA1D receptor antagonist 1 (free base) can be used in studies of overactive bladder disorders such as urinary urgency, frequency and incontinence.

SaRI 59-801 is an orally effective hypoglycemic compound with stimulation activity of insulin secretion. SaRI 59-801 decreases blood glucose in several species and to elevate plasma insulin in rats and mice.

KF20274 is an orally active adenosine A₁ receptor antagonist. KF20274 increases the fecal pellet output in rats, and does not affect small intestinal propulsion or gastric emptying at defecation-increasing doses. KF20274 does not induce diarrhea at defecation-increasing doses. KF20274 can be used for the research of constipation.

N,N'-Methylenebisacrylamide-d₆ is the deuterium labeled N,N'-Methylenebisacrylamide (HY-D0848). N,N'-Methylenebisacrylamide (Bisacrylamide) is an orally active acrylamide dimer and crosslinker. N,N'-Methylenebisacrylamide increases CYP2E1, P53, cleaved caspase-3. N,N'-Methylenebisacrylamide promotes hepatic cancer. N,N'-Methylenebisacrylamide changes sperm abnormality rate and sperm count. N,N'-Methylenebisacrylamide decreases the number of various cells in the blood as well as induces liver and testicular damage. N,N'-Methylenebisacrylamide is used to prepare polyacrylamide gel.

Elagolix-¹³C,d₃ (sodium) is the ¹³C- and deuterium labeled Elagolix sodium. Elagolix sodium is a human GnRH receptor (GnRHR) antagonist with an IC50 and Ki of 0.25 and 3.7 nM, respectively.

2'-Deoxyadenosine-¹⁵N₁ is the ¹⁵N-labeled 2'-Deoxyadenosine (HY-W040329). 2′-Deoxyadenosine is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine inhibits the growth of various cells. 2'-Deoxyadenosine has an anticancer effect on colon cancer.

Exemestane-¹³C₃ is the ¹³C-labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research.